ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy
… ProQR to Present Axiomer RNA Editing Platform Technology at … & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Platenburg, co-founder and Chief Innovation Officer of ProQR. “With this approach disease-causing mutations can be …
ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5Rx, jetzt QR-1123, für autosomal-dominante Retinitis pigmentosa (adRP), eine seltene vererbte Form der Blindheit ohne zugelassene Therapie
… ProQR to Present at 3rd Annual Evercore ISI Virtual … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under ‘ Events ’. The archived webcast will …
… ProQR Announces Successful Defense of a Key Axiomer® Patent … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3234134 B1 , which is related to …
… ProQR Announces Additional Sepofarsen Illuminate Trial … top-line announcement in February 2022 that Illuminate , ProQR’s pivotal Phase 2/3 trial of sepofarsen in CEP290 … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… ProQR to Focus Exclusively on Axiomer RNA-editing Technology … & CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …